OverviewSuggest Edit

VolitionRx is a life sciences company which focuses on developing blood-based tests to diagnose a range of cancers. The Company is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It also develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to decide on appropriate therapy, NuQ tests for non-cancer conditions, and NuQ clinical diagnostic products. 

TypePublic
Founded2010
HQSingapore, SG
Websitevolitionrx.com

Latest Updates

Employees (est.) (Dec 2018)44(+19%)
Revenue (FY, 2014)$14.8 K
Share Price (Jun 2019)$3.1 (+5%)

Key People/Management at VolitionRX

Cameron Reynolds

Cameron Reynolds

President & Chief Executive Officer
David Vanston

David Vanston

Group Chief Financial Officer
Jake Micallef

Jake Micallef

Chief Scientific Officer
Louise Day

Louise Day

Chief Marketing and Communications Officer
Gaetan Michel

Gaetan Michel

Chief Executive Officer of Belgian Volition SPRL
Jasmine Kway

Jasmine Kway

Chief Executive Officer, Singapore Volition
Show more

VolitionRX Office Locations

VolitionRX has offices in Singapore, Isnes, London and Austin
Singapore, SG (HQ)
1 Scotts Road #24-05 Shaw Centre
Isnes, BE
22 Rue Phocas Lejeune Parc Scientifique Crealys
London, GB
93-95 Gloucester Place
Austin, US
100 Congress Ave
Show all (4)

VolitionRX Financials and Metrics

VolitionRX Revenue

VolitionRX's revenue was reported to be $14.79 k in FY, 2014
USD

Net income (Q2, 2019)

(4.2m)

EBIT (Q2, 2019)

(4.1m)

Market capitalization (10-Jun-2019)

123.6m

Closing stock price (10-Jun-2019)

3.1

Cash (30-Jun-2019)

18.5m

EV

107.6m
VolitionRX's current market capitalization is $123.6 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

14.8k

Sales and marketing expense

666.4k763.4k1.2m

General and administrative expense

434.0k669.0k741.7k5.4m5.8m

R&D expense

2.5m6.1m6.8m8.9m10.9m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

14.8k

Sales and marketing expense

148.6k152.6k134.7k364.1k235.4k259.3k284.3k238.1k

General and administrative expense

68.9k51.8k129.3k247.8k122.4k141.4k228.2k166.1k163.9k244.2k258.7k226.6k1.8m1.6m1.5m1.2m1.4m

R&D expense

870.5k791.3k1.1m1.2m1.4m1.9m1.5m1.8m2.0m1.8m1.7m2.2m2.4m2.7m2.7m2.5m2.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

888.7k2.1m5.9m21.7m10.1m13.4m

Accounts Receivable

1.8m

Inventories

Current Assets

1.0m2.3m6.2m22.0m10.6m13.9m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

2.8m1.8m2.4m11.0m9.3m6.9m17.0m14.5m12.5m18.5m16.5m13.8m14.3m11.9m16.4m16.2m18.5m

Current Assets

2.9m2.0m2.7m11.3m9.7m7.3m17.4m14.9m12.9m19.0m17.0m14.3m14.9m12.5m17.1m17.1m19.2m

PP&E

74.9k94.6k315.8k256.9k887.7k853.6k763.9k757.6k725.1k3.0m3.4m3.5m3.5m3.3m3.2m3.0m3.0m

Total Assets

4.0m3.0m3.8m12.4m11.3m8.9m18.9m16.4m14.3m22.5m21.0m18.4m19.0m16.3m20.7m20.6m22.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(3.7m)(8.2m)(9.5m)(11.9m)(14.8m)(18.0m)

Depreciation and Amortization

146.4k142.1k236.3k309.4k528.2k636.4k

Inventories

Accounts Payable

34.7k(315.8k)1.1m(339.7k)65.8k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(2.2m)(1.4m)(5.9m)(2.0m)(3.9m)(6.8m)(2.5m)(2.9m)(8.9m)(3.4m)(6.8m)(10.7m)(4.7m)(9.2m)(13.7m)(4.2m)(8.4m)

Depreciation and Amortization

30.9k63.6k91.5k164.3k72.2k230.6k93.3k225.7k371.4k156.4k318.0k474.5k179.8k365.9k

Accounts Payable

55.5k(114.9k)(83.6k)(304.4k)286.3k872.9k166.2k(46.7k)264.3k439.9k1.4m261.4k277.4k938.4k

Cash From Operating Activities

(977.6k)(2.3m)(4.1m)(6.7m)(2.2m)(6.7m)(2.7m)(5.5m)(8.3m)(3.5m)(6.5m)(11.1m)(3.7m)(6.4m)
USDY, 2019

EV/EBIT

-35.6 x

EV/CFO

-22.8 x

Financial Leverage

1.4 x
Show all financial metrics

VolitionRX Online and Social Media Presence

Embed Graph

VolitionRX News and Updates

VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

AUSTIN, Texas, July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately $1.4 million from the Walloon Region, Belgium. To...

VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer

AUSTIN, Texas, May 7, 2019 / / -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale lung cancer …

VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

AUSTIN, Texas, May 6, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Thursday, May 9 at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2019 in addition to providing a business...

VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report

ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") hosted a Capital Markets Day at the New York Stock Exchange today to update interested parties on its recent progress. Volition has also issued a Company Update Report; a downloadable...

VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China

ISNES, Belgium, March 28, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") with an expectation of negotiating and entering...

VolitionRx Limited to Present at Conferences in March & April 2019

ISNES, Belgium, March 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations, Scott Powell, is scheduled to present at three conferences in March and April 2019. During the conferences, Dr....
Show more

VolitionRX Frequently Asked Questions

  • When was VolitionRX founded?

    VolitionRX was founded in 2010.

  • Who are VolitionRX key executives?

    VolitionRX's key executives are Cameron Reynolds, David Vanston and Jake Micallef.

  • How many employees does VolitionRX have?

    VolitionRX has 44 employees.

  • Who are VolitionRX competitors?

    Competitors of VolitionRX include VastCon, Chronix Biomedical and DiaSorin.

  • Where is VolitionRX headquarters?

    VolitionRX headquarters is located at 1 Scotts Road #24-05 Shaw Centre , Singapore.

  • Where are VolitionRX offices?

    VolitionRX has offices in Singapore, Isnes, London and Austin.

  • How many offices does VolitionRX have?

    VolitionRX has 4 offices.